OA10893A - Treatment of a hemoglobinopathy - Google Patents

Treatment of a hemoglobinopathy Download PDF

Info

Publication number
OA10893A
OA10893A OA9800189A OA9800189A OA10893A OA 10893 A OA10893 A OA 10893A OA 9800189 A OA9800189 A OA 9800189A OA 9800189 A OA9800189 A OA 9800189A OA 10893 A OA10893 A OA 10893A
Authority
OA
OAPI
Prior art keywords
patient
gas
therapeutic
ppm
oxygen
Prior art date
Application number
OA9800189A
Other languages
English (en)
Inventor
C Head Alvin
M Zapol Warren
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of OA10893A publication Critical patent/OA10893A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
OA9800189A 1996-04-05 1998-10-02 Treatment of a hemoglobinopathy OA10893A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1488696P 1996-04-05 1996-04-05

Publications (1)

Publication Number Publication Date
OA10893A true OA10893A (en) 2001-10-11

Family

ID=21768361

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800189A OA10893A (en) 1996-04-05 1998-10-02 Treatment of a hemoglobinopathy

Country Status (15)

Country Link
US (1) US5885621A (de)
EP (1) EP0914103B1 (de)
JP (1) JP2000510448A (de)
CN (1) CN1208053C (de)
AP (1) AP897A (de)
AT (1) ATE331505T1 (de)
AU (1) AU720686B2 (de)
BR (1) BR9708601A (de)
CA (1) CA2251530C (de)
DE (1) DE69736230T2 (de)
DK (1) DK0914103T3 (de)
ES (1) ES2267141T3 (de)
OA (1) OA10893A (de)
PT (1) PT914103E (de)
WO (1) WO1997037644A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6911427B1 (en) 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US6197745B1 (en) 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
FR2812197B1 (fr) * 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US7335181B2 (en) * 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7238469B2 (en) * 2001-06-21 2007-07-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
EP2319518A1 (de) * 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Verwendung CO-freisetzender Verbindungen zur Behandlung entzündlicher Erkrankungen
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
KR20040096571A (ko) * 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
EP1499328B1 (de) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Verfahren zur behandlung von nekrotisierender enterocolitis
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
CA2485465A1 (en) * 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
CA2487413A1 (en) * 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶-1和血红素降解产物的药学用途
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
WO2005004884A2 (en) * 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
MXPA06013111A (es) * 2004-05-11 2007-05-23 Sensormedics Corp Dosificacion intermitente de gas de oxido nitrico.
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US7523752B2 (en) * 2005-09-21 2009-04-28 Ino Therapeutics, Llc System and method of administering a pharmaceutical gas to a patient
US8893717B2 (en) 2005-09-21 2014-11-25 Ino Therapeutics Llc Systems and methods of administering a pharmaceutical gas to a patient
WO2007057763A2 (en) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
KR20090087900A (ko) * 2006-11-07 2009-08-18 더 제너럴 하스피탈 코포레이션 혈관작용성 산소운반체에 의해 유도되는 혈관수축의 감소
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
SI3498328T1 (sl) 2009-05-27 2021-03-31 Mallinckrodt Hospital Products IP Limited Pripomoček za spajanje indeksiranega ventila in sestava posode pod tlakom s pritrdilnim obročem in za linearno sprožitev sestava sprožilnika pri odvajanju tekočin s pripomočkom za reguliranje dovajanja zdravila
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011031289A1 (en) * 2009-09-08 2011-03-17 Duke University Novel medical uses for no and no donor compounds
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
EP2763935B2 (de) 2011-10-03 2023-06-07 NitricGen, Inc. Vorrichtung und verfahren zur erzeugung von stickoxid in kontrollierten und genauen mengen
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
WO2013132497A1 (en) 2012-03-07 2013-09-12 Advanced Inhilation Therapies (Ait) Ltd. Inhalation of nitric oxide for treating respiratory diseases
CN104411317A (zh) 2012-03-15 2015-03-11 Ino治疗有限责任公司 用于施用高浓度一氧化碳的方法
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
US11779720B2 (en) 2019-11-04 2023-10-10 Vapotherm, Inc. Methods, devices, and systems for improved oxygenation patient monitoring, mixing, and delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
DE69127756T2 (de) * 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
AU704173B2 (en) * 1993-11-02 1999-04-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury

Also Published As

Publication number Publication date
DK0914103T3 (da) 2006-10-23
AU720686B2 (en) 2000-06-08
PT914103E (pt) 2006-09-29
CA2251530C (en) 2002-11-19
US5885621A (en) 1999-03-23
EP0914103A4 (de) 2003-09-03
CN1208053C (zh) 2005-06-29
ES2267141T3 (es) 2007-03-01
EP0914103B1 (de) 2006-06-28
CN1227485A (zh) 1999-09-01
AU2440397A (en) 1997-10-29
JP2000510448A (ja) 2000-08-15
WO1997037644A1 (en) 1997-10-16
AP897A (en) 2000-11-17
EP0914103A1 (de) 1999-05-12
DE69736230D1 (de) 2006-08-10
DE69736230T2 (de) 2007-05-31
AP9801358A0 (en) 1998-12-31
ATE331505T1 (de) 2006-07-15
BR9708601A (pt) 1999-08-03
CA2251530A1 (en) 1997-10-16

Similar Documents

Publication Publication Date Title
EP0914103B1 (de) Behandlung einer hämoglobinstörung
EP1229954B1 (de) Verfahren zur behandlung von herz-lungenerkrankungen mittels verbindungen aus der no-gruppe
Head et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
Young et al. Effect of low concentrations of ozone on pulmonary function in man
EP1516639B2 (de) Verwendung von NO zur Behandlung der persistenten pulmonaren Hypertonie des Neugeborenen
US7945301B2 (en) Methods and apparatus for the administration of CO
HUP9802093A2 (hu) Nitrogén-monoxid alkalmazása érrendszeri trombózis és restenózis kezelésére alkalmas gyógyszerkészítmény előállítására
Jacobs et al. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury
Santiago et al. Mechanism of the ventilatory response to carbon monoxide.
Steffey et al. Alterations in horse blood cell count and biochemical values after halothane anesthesia
Geller et al. Cyanide toxicity from acetonitrile-containing false nail remover
Santiago et al. The effect of anemia on the ventilatory response to transient and steady-state hypoxia.
Albertson et al. A case of fatal sodium azide ingestion
Miller et al. Mechanism of erythropoietin production by cobaltous chloride
EP1712226A2 (de) Behandlung von einem Hemoglobinopathy
HIKASA et al. Sevoflurane anesthesia following administration of atropine-guaifenesin-thiopental in spontaneous-breathing adult cattle
Bigelow et al. The effect of oxygen breathing on arterial blood gases in patients with chronic airway obstruction living at 5,200 feet
MXPA98008195A (es) Tratamiento de una hemoglobinopatia
Ten Eyck et al. Comparison of nitrite treatment and stroma-free methemoglobin solution as antidotes for cyanide poisoning in a rat model
Hubmayr et al. Acute and long-term effects of Fluosol-DA 20% on respiratory system mechanics and diffusion capacity in dogs
Grover et al. Inhaled Nitric Oxide Therapy